RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA®

• RedHill received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering BEKINDA^® (RHB-102), expected to be valid until at least 2034, once granted
• BEKINDA^® is a proprietary, bimodal extended-release, once-daily oral pill formulation of ondansetron, targeting several gastrointestinal indications
• Top-line results from a Phase III study with BEKINDA^® 24 mg for acute gastroenteritis and gastritis (the GUARD study) are expected in the second quarter of 2017
• A Phase II study with BEKINDA^® 12 mg for diarrhea-predominant irritable bowel syndrome (IBS-D) is ongoing, with top-line results expected in the third quarter of 2017
• RedHill will host an R&D Day and live webcast on BEKINDA^® on Thursday, April 27, 2017 in NYC, discussing the product, indications, potential markets and the ongoing Phase III and II studies for acute gastroenteritis and IBS-D, respectively

TEL-AVIV, Israel, April 19 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it has received notices of allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering BEKINDA^® (RHB-102)¹. Once granted, the patents are expected to be valid until at least 2034.

Danielle Abramson, Ph.D., RedHill’s Director of Intellectual Property & Research said: “We are very pleased with the allowance of two additional U.S. patents for BEKINDA^®. This is an important addition to RedHill’s strong IP portfolio, that will further enhance our protection of BEKINDA^®. We are approaching significant milestones with BEKINDA^® in the coming months, with top-line results from the Phase III study for gastroenteritis and gastritis expected in the second quarter of 2017 and top-line results from the Phase II for IBS-D expected in the third quarter of 2017.”

SOURCE : RedHill Biopharma Ltd.